Molecular basis of the VHL hereditary cancer syndrome
The DOI matches its Crossref record; 145 of the 146 references it cites were found in a registry or an index.
Abstract
The von Hippel-Lindau hereditary cancer syndrome was first described about 100 years ago. The unusual clinical features of this disorder predicted a role for the von Hippel-Lindau gene (VHL) in the oxygen-sensing pathway. Indeed, recent studies of this gene have helped to decipher how cells sense changes in oxygen availability, and have revealed a previously unappreciated role of prolyl hydroxylation in intracellular signalling. These studies, in turn, are laying the foundation for the treatment of a diverse set of disorders, including cancer, myocardial infarction and stroke.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the PHDs utilize ␣-ketoglutarate as a cosubstrate and require ferrous iron (Fe 2ϩ ) and ascorbate as cofactors (Kaelin, 2002;Schofield and Zhang, 1999).”
From Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase (2005) · cites this paper as Kaelin, 2002
In the citing paper
“Since pVHL binding to the ODD domain is dependent on PHD activity (Kaelin, 2002;Safran and Kaelin, 2003)”
From Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase (2005) · cites this paper as Kaelin, 2002
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 1×
“The interaction of pVHL with HIF-α is governed by the enzymatic hydroxylation of conserved proline residues that are located within highly conserved, peptidic, pVHL-binding domains within the HIF-α subunit”
BackgroundEpstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F.-M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,973
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Regulation of Mammalian O 2 Homeostasis by Hypoxia-Inducible Factor 1
Semenza, G. L. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.551 · Cited by 1,914
Mutations of the VHL tumour suppressor gene in renal carcinoma
Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-85 · Cited by 1,730
HIF‐1α is required for solid tumor formation and embryonic vascularization
Ryan, H. E., Lo, J., & Johnson, R. S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3005 · Cited by 1,579
Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577
Self-citation
Research works printed but not linked: 5
- Collins, E. T. Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes). Trans. Ophthalmol. Soc. UK 14, 141–149 (1894).
- Clifford, S., Prowse, A., Affara, N., Buys, C. & Maher, E. Inactivation of the von Hippel–Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosom. Cancer 22, 200–209 (1998). · DOI · Paper page
- Gallou, C. et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum. Mutat. 13, 464–475 (1999). · DOI
- Ivan, M. et al. Biochemical purification and pharmacological inhibition of a mammalian HIF prolyl hydroxylase. Proc. Natl Acad. Sci. USA (in the press).
- Aiello, L. et al. Rapid and durable recovery of visual function in a patient with von Hippel–Lindau syndrome and optic nerve head hemangioma following systemic treatment with the VEGF receptor inhibitor SU5416. Ophthalmology (in the press).
Cited by
Items 501–600 of 864
Rehder, H. (2008) · Wiley eBooks · doi:10.1002/9783527627523.ch3 · Cited by 16
Joaquim Bellmunt, B. (2007) · European Urology Supplements · doi:10.1016/j.eursup.2007.01.018 · Cited by 14
Luo, W., Xu, Z., Li, F., Ding, L., Wang, R., Lin, Y., Mao, X., Chen, X., Li, Y., Lu, Z., et al. (2024) · Advanced Science · doi:10.1002/advs.202404033 · Cited by 16
Singh, K. P., & Roy, D. (2007) · Gene · doi:10.1016/j.gene.2007.10.022 · Cited by 13
Lim, J. H., Jung, C., Lee, C., & Im, D. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21914 · Cited by 15
Takamori, H., Yamasaki, T., Kitadai, R., Minamishima, Y. A., & Nakamura, E. (2023) · Cancer Science · doi:10.1111/cas.15728 · Cited by 14
von Hippel-Lindau Disease and Pregnancy: What an Obstetrician Should Know
Adekola, H., Soto, E., Lam, J., Bronshtein, E., Chaiworapongsa, T., & Sorokin, Y. (2013) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e3182a85063 · Cited by 14
Marques, A., & Portugal, R. V. (2019) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000628 · Cited by 13
Liu, H., Shi, J., Wang, H. L., Zhang, J., Brown, R. E., Wilkerson, M. L., & Lin, F. (2012) · PubMed · Cited by 13
Igaz, P., Wiener, Z., Szabó, P. M., Falus, A., Gaillard, R. C., Horányi, J., Rácz, K., & Tulassay, Z. (2006) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2006.06.011 · Cited by 13
The role of immunomodulatory metabolites in shaping the inflammatory response of macrophages
Park, D., Lim, G., Yoon, S., Yi, H., & Choi, D. W. (2022) · BMB Reports · doi:10.5483/bmbrep.2022.55.11.128 · Cited by 13
Hypoxia stabilizes SETDB1 to maintain genome stability
Park, S., Cho, J. H., Kim, J.-H., Park, S., (18229615), S. P., Kim, S., Kim, S., Kim, K., Park, B. C., Park, B. C., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad796 · Cited by 12
Advances in cancer genomics and precision oncology
Heo, Y., Kim, W., Cho, Y., Jung, J., Kim, N., & Choi, I. (2025) · Genes & Genomics · doi:10.1007/s13258-024-01614-7 · Cited by 13
Schovánek, J., Bullova, P., Tayem, Y. I., Giubellino, A., WESLEY, R. A., Lendvai, N. K., Nölting, S., Kopáček, J., Fryšák, Z., Pommier, Y. G., et al. (2015) · Endocrinology · doi:10.1210/en.2015-1476 · Cited by 13
Identification of pVHL as a Novel Substrate for Aurora-A in Clear Cell Renal Cell Carcinoma (ccRCC)
Martin, B., Chesnel, F., Delcros, J., Jouan, F., Couturier, A., Dugay, F., Goff, X. L., Patard, J., Fergelot, P., Vigneau, C. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067071 · Cited by 12
Chen, S., Chew, E. Y., & Chan, C. (2015) · Journal of Medical Case Reports · doi:10.1186/s13256-015-0539-2 · Cited by 12
Imaging Findings of Pancreatic Cystic Lesions in von Hippel-Lindau Disease
Kobayashi, N., Sato, T., Kato, S., Watanabe, S., Hosono, K., Shimamura, T., Iida, H., Endo, H., Koide, T., Takahashi, H., et al. (2012) · Internal Medicine · doi:10.2169/internalmedicine.51.7194 · Cited by 12
Chen, Y., Zhu, L., Xue, S., Shi, J., He, C., & Zhang, Q. (2021) · Oncology Letters · doi:10.3892/ol.2021.12640 · Cited by 14
Hipoxia tumoral: Papel del factor inducible por hipoxia
Fraga, A. M., Ribeiro, R. J. T., & Medeiros, R. (2009) · Actas Urológicas Españolas · doi:10.4321/s0210-48062009000900003 · Cited by 12
Ohh, M. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.016 · Cited by 13
Shang, D., Xu, X., Wang, D., Li, Y., & Liu, Y. (2013) · World Journal of Urology · doi:10.1007/s00345-013-1077-4 · Cited by 12
Blouw, B., Haase, V. H., Song, H., Bergers, G., & Johnson, R. S. (2007) · Oncogene · doi:10.1038/sj.onc.1210249 · Cited by 12
New cancer targets emerging from studies of the Von Hippel‐Lindau tumor suppressor protein
Kaelin, W. G. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05781.x · Cited by 12
Self-citationCapillary Hemangioblastoma of the Retina and von Hippel–Lindau Disease
Chew, E. Y., & SCHACHAT, A. P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00130-2 · Cited by 12
Cancer of the Central Nervous System
Dorsey, J. F., Hollander, A. B., Alonso‐Basanta, M., Macyszyn, L., Bohman, L., Judy, K. D., Maity, A. M., Lee, J. Y. K., Lustig, R. A., Phillips∥, P. C., et al. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00066-7 · Cited by 13
Lassau, N., Chebil, M., Chami, L., & Roche, A. J. (2008) · Targeted Oncology · doi:10.1007/s11523-008-0081-x · Cited by 12
The Importance of Pathology and Genetics for the Diagnosis and Therapy of Renal Cell Carcinoma
Störkel, S., Kristiansen, G., & Moch, H. (2007) · European Urology Supplements · doi:10.1016/j.eursup.2007.03.004 · Cited by 12
Owoicho, A. M., Ogenyi, D. O., Zhilenkova, A. V., Essogmo, F. E., Tchawe, Y. S. N., Uchendu, I. K., Pascal, A. M., Nikitina, N. M., Rusanov, A. S., Sanikovich, V. D., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010265 · Cited by 15
Genetics of Pancreatic Neuroendocrine Tumors
Mohindroo, C., McAllister, F. M., & Jesus‐Acosta, A. D. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.07.005 · Cited by 12
Novel genotype–phenotype correlations in five Chinese families with Von Hippel–Lindau disease
Liu, Q., Yuan, G., Tong, D., Liu, G., Yi, Y., Zhang, J., Zhang, Y., Wang, L.-A., Wang, L., Zhang, D., et al. (2018) · Endocrine Connections · doi:10.1530/ec-18-0167 · Cited by 11
Oxymatrine Inhibits Renal Cell Carcinoma Progression by Suppressing β-Catenin Expression
Jin, Y., Liu, J., Liu, Y., Liu, Y., Guo, G., Yu, S., & An, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00808 · Cited by 13
Hereditary ovarian tumour syndromes: current update on genetics and imaging
Shanbhogue, K., Prasad, A. S., Ucisik, F. E., Katabathina, V. S., & Morani, A. C. (2021) · Clinical Radiology · doi:10.1016/j.crad.2020.11.116 · Cited by 10
Seven Novel Genes Related to Cell Proliferation and Migration of VHL-Mutated Pheochromocytoma
Gao, S., Liu, L., Li, Z., Pang, Y., Shi, J., & Zhu, F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.598656 · Cited by 12
Pathology of the Nervous System in Von Hippel-Lindau Disease
Vortmeyer, A. O., & Alomari, A. K. (2015) · Journal of Kidney Cancer and VHL · doi:10.15586/jkcvhl.2015.35 · Cited by 12
Martín-Puig, S., Temes, E., Olmos, G., Jones, D., Aragonés, J., & Landázuri, M. O. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310658200 · Cited by 12
Abu‐Remaileh, M., Persky, N. S., Lee, Y., Root, D. E., & Kaelin, W. G. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2410356121 · Cited by 9
Self-citationNME genes in epithelial morphogenesis
Hsu, T. (2011) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-011-0607-0 · Cited by 12
Epigenetics in advanced renal cell carcinoma: Potential new targets
Molina‐Cerrillo, J., Santoni, M., Ruiz, Á., Massari, F., Pozas, J., Ortego, I., Gómez, V., Grande, E., & Alonso‐Gordoa, T. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103857 · Cited by 10
Zhang, L., Xu, B., Wang, Y., Liu, C., Lǚ, K., Huang, Y., Liu, N., Zhang, X., Chen, S., & Chen, M. (2015) · Oncology Letters · doi:10.3892/ol.2015.3279 · Cited by 10
Lang, G., Shi, J., Huang, L., Cao, A., Zhang, C., Song, C., Zhuang, Z., Hu, X., Huang, W., & Shao, Z. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-2999 · Cited by 13
Angiogenesis in triple-negative adenoid cystic carcinomas of the breast
Vranić, S., Frković‐Grazio, S., Bilalović, N., & Gatalica, Z. (2011) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-011-1144-4 · Cited by 10
Hemangioblastoma Stromal Cells Show Committed Stem Cell Phenotype
Welten, C. M., Keats, E. C., Ang, L.-C., & Khan, Z. A. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100015675 · Cited by 11
Prindull, G. (2005) · Stem Cell Reviews and Reports · doi:10.1385/scr:1:3:277 · Cited by 13
The role of metabolic reprogramming in kidney cancer
Chen, Z., & Zhang, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1402351 · Cited by 13
BBOX1 restrains TBK1-mTORC1 oncogenic signaling in clear cell renal cell carcinoma
Liao, C., Hu, L., Jia, L., Zhou, J. R., Wang, T., Kim, K., Zhong, H., Yao, H., Dong, L., Guo, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56955-y · Cited by 11
Teisseire, M., Sahu, U., Parola, J., Tsai, M., Vial, V., Durivault, J., Grépin, R., Cormerais, Y., Molina, C., Gouraud, A., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-1393 · Cited by 14
Hu, L., Zhang, Y., Guo, L., Zhong, H., Xie, L., Zhou, J. R., Liao, C., Yao, H., Fang, J. Q., Liu, H., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2023.12.010 · Cited by 10
A c.464T>A mutation in VHL gene in a Chinese family with VHL syndrome
Lu, Y., Lu, J., Liu, Q., Niu, J., Zhang, S.-M., Wu, Q., & Qi, X. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-1015-0 · Cited by 11
VHL down-regulation and differential localization as mechanisms in tumorigenesis
Shiao, Y., Försti, A., Egevad, L., Anderson, L. M., Lindblad, P., & Hemminki, K. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00257.x · Cited by 9
Loss of PL6 protein expression in renal clear cell carcinomas and other VHL‐deficient tumours
Иванова, А. В., Vortmeyer, A. O., Ivanov, S. V., Nickerson, M. L., Maher, E. R., & Lerman, M. I. (2007) · The Journal of Pathology · doi:10.1002/path.2252 · Cited by 10
Retinal Manifestations of the Phakomatoses
Haug, S. J., & Stewart, J. M. (2011) · International Ophthalmology Clinics · doi:10.1097/iio.0b013e31823bbb7a · Cited by 9
Neurological Management of Von Hippel-Lindau Disease
Hodgson, T. S., Nielsen, S. M., Lesniak, M. S., & Lukas, R. V. (2016) · The Neurologist · doi:10.1097/nrl.0000000000000085 · Cited by 11
Targeting Metabolic Pathways in Kidney Cancer: Rationale and Therapeutic Opportunities
Hoerner, C. R., Miao, S. Y., Hsieh, J. J.-D., & Fan, A. C. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000472 · Cited by 9
Analysis of von Hippel–Lindau Hereditary Cancer Syndrome: Implications of Oxygen Sensing
Yang, H., Ivan, M., Min, J., Kim, W. Y., & Kaelin, W. G. (2004) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(04)81022-x · Cited by 11
Self-citationJuxtapapillary retinal capillary hemangioma: A clinical and histopathological case report
Al-Essa, R. S., Helmi, H. A., Alkatan, H. M., & Maktabi, A. M. (2021) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2021.01.014 · Cited by 9
The 5th Kidney Cancer Research Summit: Research Accelerating Cures for Renal Cell Carcinoma in 2023
Choueiri, T. K., Pal, S. K., Lewis, B., Poteat, S., Pels, K., & Hammers, H. J. (2023) · The Oncologist · doi:10.1093/oncolo/oyad322 · Cited by 8
Diagnostic, prognostic, and therapeutic potential of exosomal microRNAs in renal cancer
Yu, X., Du, Z., Zhu, P., & Liao, B. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00568-7 · Cited by 11
Cicchetti, R., Basconi, M., Litterio, G., Mascitti, M., Tamborino, F., Orsini, A., Digiacomo, A., Ferro, M., Schips, L., & Marchioni, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25169060 · Cited by 11
Yang, W., Wu, W., Zhao, Y., Li, Y., Zhang, C., Zhang, J., Chen, C., & Cui, S. (2022) · Cell Biology International · doi:10.1002/cbin.11890 · Cited by 7
Gavrilova, A. A., Fefilova, A. S., Vishnyakov, I. E., Константинович, Т. К., Константинович, Т. К., Uversky, V. N., & Fonin, A. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098108 · Cited by 7
Hypoxia and Tumour Angiogenesis
Brahimi-Horn, M. C., Laferrière, J., Mazure, N. M., & Pouysségur, J. (2007) · Springer eBooks · doi:10.1007/978-3-540-33177-3_10 · Cited by 12
Fujisue, Y., Nakagawa, T., Takahara, K., Inamoto, T., Kiyama, S., Azuma, H., & Asahi, M. (2013) · Oncology Letters · doi:10.3892/ol.2013.1283 · Cited by 8
Sevilla‐Montero, J., Bienes-Martínez, R., Labrousse-Arias, D., Fuertes-Yebra, E., Ordóñez, Á., & Calzada, M. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-58137-w · Cited by 9
Magdaleno, C., Dixon, L., Rajasekaran, N., & Varadaraj, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-75756-5 · Cited by 8
Wang, X., Xiao, Y., Li, S., Yan, Z., & Luo, G. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.647301 · Cited by 11
Walsh, M. F., Cadoo, K. A., Salo‐Mullen, E. E., Dubard-Gault, M. E., Stadler, Z. K., & Offit, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00013-x · Cited by 11
Les anti-angiogéniques : de nouveaux standards thérapeutiques dans le cancer du rein métastatique
Cornu, J., Morgan Rouprêt, A., Bensalah, K., Oudard, S. M., & Patard, J. (2008) · The French Journal of Urology · doi:10.1016/s1166-7087(08)73665-0 · Cited by 8
Functional Annotation of Deubiquitinating Enzymes Using RNA Interference
Dirac, A. M. G., Nijman, S. M. B., Brummelkamp, T. R., & Bernards, R. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)98045-2 · Cited by 8
7.2 Genetics and Gene Expression of Glycolysis
LaManna, J. C., Pichiule, P., & Chavez, J. C. (2007) · Springer eBooks · doi:10.1007/978-0-387-30411-3_28 · Cited by 8
VHL Inactivation: A New Road to Senescence
Kim, W. Y., & Sharpless, N. E. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.03.012 · Cited by 11
Determining the optimal dose and schedule of sunitinib
Suárez, C., & Rini, B. I. (2011) · Cancer · doi:10.1002/cncr.26426 · Cited by 8
Jung, N. Y., & Park, J. B. (2025) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2025.0018 · Cited by 8
Mitochondrial VHL rewires cell metabolism in hypoxia
Li, G., Pan, W., Wu, L., Cai, Z., Chen, H., Wu, X., Yu, T., Liao, K., Zhang, H., 温星桥, et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.11.013 · Cited by 13
Posterior Pole and Peripheral Retinal Fibrovascular Proliferation in von Hippel Lindau Disease
Elborgy, E. S., & Pulido, J. S. (2017) · Asia-Pacific Journal of Ophthalmology · doi:10.22608/apo.2016205 · Cited by 7
The E3 ubiquitin-protein ligase MDM2 is a novel interactor of the von Hippel–Lindau tumor suppressor
Falconieri, A., Minervini, G., Bortolotto, R., Piovesan, D., Lopreiato, R., Sartori, G., Pennuto, M., & Tosatto, S. C. E. (2020) · Scientific Reports · doi:10.1038/s41598-020-72683-3 · Cited by 7
Loss of VHL-mediated pRb regulation promotes clear cell renal cell carcinoma
Akuma, M., Kim, M., Zhu, C., Wiljer, E., Gaudreau-Lapierre, A., Patterson, L. D., Egevad, L., Tanguay, S., Trinkle‐Mulcahy, L., Stanford, W. L., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07623-y · Cited by 11
Genomic profiles of renal cell carcinoma in a small Chinese cohort
Tai, S., Xu, D., Yu, Z., Guan, Y., Yin, S., Xiao, J., Xue, S., & Liang, C. Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1095775 · Cited by 7
Concurrent bilateral pheochromocytoma and thoracic paraganglioma during pregnancy
Snabboon, T., Plengpanich, W., Houngngam, N., Buranasupkajorn, P., Plengvidhya, N., Sereepapong, W., Sunthornyothin, S., & Shotelersuk, V. (2010) · Endocrine · doi:10.1007/s12020-009-9292-x · Cited by 7
Yu, W., Zhao, S., Zhao, Y., Fatema, C. N., Murakami, M., Nishijima, K., Kitagawa, Y., Tamaki, N., & Kuge, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.6371 · Cited by 7
The Effect of Targeted Therapy for Genitourinary Malignancies on Sexual Function and Fertility
Holland, B. C., Shetty, Z., & Alanee, S. R. (2017) · Current Urology Reports · doi:10.1007/s11934-017-0704-9 · Cited by 7
Oncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm?
Lawson, K. A., & Morris, D. G. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.685713 · Cited by 7
Systemic Therapy of Kidney Cancer: Tyrosine Kinase Inhibitors, Antiangiogenesis or IL-2?
Kırkalı, Z., & Tüzel, E. (2009) · Future Oncology · doi:10.2217/fon.09.51 · Cited by 7
Analysis of succinate dehydrogenase subunit B gene alterations in gastric cancers
Cao, Z., Song, J. H., Kang, Y. W., Yoon, J., Nam, S. W., Lee, J. Y., & Park, W. S. (2010) · Pathology International · doi:10.1111/j.1440-1827.2010.02558.x · Cited by 8
Molecular Analysis as a Tool in the Differential Diagnosis of VHL Disease-Related Tumors
Gijtenbeek, J. M. M., Jacobs, B., Boots‐Sprenger, S., Bonné, A., Lenders, J. W. M., K�sters, B., Wesseling, P., & Jeuken, J. W. M. (2005) · Diagnostic Molecular Pathology · doi:10.1097/01.pas.0000155022.42944.73 · Cited by 7
Inflammatory Breast Cancer: Yet Another Risk of the Obesity Epidemic?
Amiri‐Kordestani, L., Kamangar, F., & Zujewski, J. A. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt236 · Cited by 7
Zou, Y., Wang, Z., Jiang, Q., Kong, X., Ma, X., Liang, Z., Wang, Z., Chen, B., Yuan, J., Wen, J., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2500562122 · Cited by 14
Rationale for immune checkpoint inhibitors plus targeted therapy for advanced renal cell carcinoma
Yang, S., Yang, X., Hou, Z., Zhu, L., Yao, Z., Zhang, Y., Chen, Y., Teng, J., Fang, C., Chen, S., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29215 · Cited by 10
Dysregulation of ubiquitination modification in renal cell carcinoma
You, H., Zhang, H., Jin, X., & Yan, Z. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1453191 · Cited by 7
Wen, Z., Wu, Y., Zhao, Z., Li, R., Li, X., Lu, C., Sun, C., Chen, W., Ge, Z., Ni, L., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-023-03187-z · Cited by 7
Minami, T., Minami, T., Shimizu, N., Yamamoto, Y., Velasco, M. D., 野澤昌弘, Yoshimura, K., Harashima, N., Harada, M., & Uemura, H. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.02.018 · Cited by 6
Functional Residues in Proteins
Ahmad, S., Wang, J., Ahmad, Z., & Ahmad, F. (2011) · Journal of Amino Acids · doi:10.4061/2011/606354 · Cited by 13
Zou, Y., XU, J., & Zhang, M. (2016) · Oncology Letters · doi:10.3892/ol.2016.4387 · Cited by 6
Cauda Equina Syndrome as First Manifestation of von Hippel-Lindau Disease
Chen, X., Xu, G., Bi, Q., Huang, Y., Shao, H., Jin, M., Mesfin, A., & Zhang, J. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.01.269 · Cited by 6
Liu, Z., Li, L., Yi, Z., Duan, H., Lu, R., Li, C., Zhou, J., & Gong, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00703 · Cited by 6
CLN5 in heterozygosis may protect against the development of tumors in a VHL patient
de Rojas-P, I., Albiñana, V., Recio-Poveda, L., Rodriguez-Rufián, A., Cuesta, Á. M., & Botella, L. M. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01410-y · Cited by 6
Tumor Suppressors APC and VHL: Gatekeepers of the Intestine and Kidney
Giles, R. H., & Voest, E. E. (2005) · Springer eBooks · doi:10.1007/3-540-27671-8_7 · Cited by 6
Genetic Factors: Hereditary Cancer Predisposition Syndromes
Offit, K., Thom, P., & Bernstein, D. B. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50015-4 · Cited by 7
Genetic Predisposition and Genetic Susceptibility
Merks, J. H. M., & Brecht, I. B. (2011) · Pediatric oncology · doi:10.1007/978-3-642-04197-6_6 · Cited by 6
Screening of Tissue Microarrays for Ubiquitin Proteasome System Components in Tumors
Lehman, N. L., van de Rijn, M., & Jackson, P. K. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)99023-x · Cited by 6
Rubin, J. S., & Bottaro, D. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1077 · Cited by 6
Metadata
- Authors
- Kaelin, W. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Kaelin, William G.
- ORCID
- Kaelin, William G.
- Venue
- Nature Reviews Cancer
- Published
- 2002-09
- Volume
- 2
- Issue
- 9
- Pages
- 673-682
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2093776019
- Semantic Scholar
- 6b13bcf0623256d5dceb071144a84d45b84f9a99
- Cited by
- 865
- References
- 146
- Citations by year
- 2026: 18 · 2025: 29 · 2024: 25 · 2023: 21 · 2022: 24 · 2021: 25 · 2020: 34 · 2019: 32 · 2018: 28 · 2017: 22 · 2016: 27 · 2015: 29 · 2014: 39 · 2013: 42 · 2012: 46
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- von Hippel-Lindau disease, VHL gene, hereditary cancer, oxygen sensing, prolyl hydroxylation, hypoxia signaling, tumour suppressor, cancer therapy
- MeSH terms
- Animals, von Hippel-Lindau Disease, Humans, Ligases, Neoplasms, Gene Expression Regulation, Neoplastic, Genetic Predisposition to Disease, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Von Hippel-Lindau Tumor Suppressor Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.